Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients

Ophélie Fourdinier, Eva Schepers, Valérie Metzinger-Le Meuth, Griet Glorieux, Sophie Liabeuf, Francis Verbeke, Raymond Vanholder, Benjamin Brigant, Anneleen Pletinck, Momar Diouf, Stéphane Burtey, Gabriel Choukroun, Ziad A. Massy, Laurent Metzinger (Corresponding Author), Angel Argiles, Joachim Beige, Philippe Brunet, Gerald Cohen, Omar Abou Deif, Pieter Evenepoel & 20 others Danilo Fliser, Ivo Fridolin, Andreas Gmerek, Joachim Jankowski, Vera Jankowski, Roos Masereeuw, Harald Mischak, Alberto Ortiz, Alessandra Perna, Juan Mariano Rodriguez-Portillo, Joost Schanstra, Goce Spasovski, Dimitrios Stamatialis, Sonja Steppan, Markus Storr, Bernd G. Stegmayr, Peter Stenvinkel, Paul J. Thornalley, Andrej Wiecek,

Research output: Contribution to journalArticleAcademicpeer-review

8 Downloads (Pure)

Abstract

Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.

Original languageEnglish
Article number4477
JournalScientific reports
Volume9
Issue number1
DOIs
Publication statusPublished - 14 Mar 2019

Fingerprint

Chronic Renal Insufficiency
Serum
Mortality
MicroRNAs
Kidney
Renal Replacement Therapy
Kidney Diseases
Disease Progression
Cardiovascular Diseases
Survival Rate

Cite this

Fourdinier, O., Schepers, E., Metzinger-Le Meuth, V., Glorieux, G., Liabeuf, S., Verbeke, F. (2019). Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. Scientific reports, 9(1), [4477]. https://doi.org/10.1038/s41598-019-41101-8
Fourdinier, Ophélie ; Schepers, Eva ; Metzinger-Le Meuth, Valérie ; Glorieux, Griet ; Liabeuf, Sophie ; Verbeke, Francis ; Vanholder, Raymond ; Brigant, Benjamin ; Pletinck, Anneleen ; Diouf, Momar ; Burtey, Stéphane ; Choukroun, Gabriel ; Massy, Ziad A. ; Metzinger, Laurent ; Argiles, Angel ; Beige, Joachim ; Brunet, Philippe ; Cohen, Gerald ; Deif, Omar Abou ; Evenepoel, Pieter ; Fliser, Danilo ; Fridolin, Ivo ; Gmerek, Andreas ; Jankowski, Joachim ; Jankowski, Vera ; Masereeuw, Roos ; Mischak, Harald ; Ortiz, Alberto ; Perna, Alessandra ; Rodriguez-Portillo, Juan Mariano ; Schanstra, Joost ; Spasovski, Goce ; Stamatialis, Dimitrios ; Steppan, Sonja ; Storr, Markus ; Stegmayr, Bernd G. ; Stenvinkel, Peter ; Thornalley, Paul J. ; Wiecek, Andrej. / Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{962036bb173e46cf9cad4e333accbbcd,
title = "Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients",
abstract = "Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.",
author = "Oph{\'e}lie Fourdinier and Eva Schepers and {Metzinger-Le Meuth}, Val{\'e}rie and Griet Glorieux and Sophie Liabeuf and Francis Verbeke and Raymond Vanholder and Benjamin Brigant and Anneleen Pletinck and Momar Diouf and St{\'e}phane Burtey and Gabriel Choukroun and Massy, {Ziad A.} and Laurent Metzinger and Angel Argiles and Joachim Beige and Philippe Brunet and Gerald Cohen and Deif, {Omar Abou} and Pieter Evenepoel and Danilo Fliser and Ivo Fridolin and Andreas Gmerek and Joachim Jankowski and Vera Jankowski and Roos Masereeuw and Harald Mischak and Alberto Ortiz and Alessandra Perna and Rodriguez-Portillo, {Juan Mariano} and Joost Schanstra and Goce Spasovski and Dimitrios Stamatialis and Sonja Steppan and Markus Storr and Stegmayr, {Bernd G.} and Peter Stenvinkel and Thornalley, {Paul J.} and Andrej Wiecek",
year = "2019",
month = "3",
day = "14",
doi = "10.1038/s41598-019-41101-8",
language = "English",
volume = "9",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Fourdinier, O, Schepers, E, Metzinger-Le Meuth, V, Glorieux, G, Liabeuf, S, Verbeke, F, Vanholder, R, Brigant, B, Pletinck, A, Diouf, M, Burtey, S, Choukroun, G, Massy, ZA, Metzinger, L, Argiles, A, Beige, J, Brunet, P, Cohen, G, Deif, OA, Evenepoel, P, Fliser, D, Fridolin, I, Gmerek, A, Jankowski, J, Jankowski, V, Masereeuw, R, Mischak, H, Ortiz, A, Perna, A, Rodriguez-Portillo, JM, Schanstra, J, Spasovski, G, Stamatialis, D, Steppan, S, Storr, M, Stegmayr, BG, Stenvinkel, P, Thornalley, PJ, Wiecek, A 2019, 'Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients' Scientific reports, vol. 9, no. 1, 4477. https://doi.org/10.1038/s41598-019-41101-8

Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. / Fourdinier, Ophélie; Schepers, Eva; Metzinger-Le Meuth, Valérie; Glorieux, Griet; Liabeuf, Sophie; Verbeke, Francis; Vanholder, Raymond; Brigant, Benjamin; Pletinck, Anneleen; Diouf, Momar; Burtey, Stéphane; Choukroun, Gabriel; Massy, Ziad A.; Metzinger, Laurent (Corresponding Author); Argiles, Angel; Beige, Joachim; Brunet, Philippe; Cohen, Gerald; Deif, Omar Abou; Evenepoel, Pieter; Fliser, Danilo; Fridolin, Ivo; Gmerek, Andreas; Jankowski, Joachim; Jankowski, Vera; Masereeuw, Roos; Mischak, Harald; Ortiz, Alberto; Perna, Alessandra; Rodriguez-Portillo, Juan Mariano; Schanstra, Joost; Spasovski, Goce; Stamatialis, Dimitrios; Steppan, Sonja; Storr, Markus; Stegmayr, Bernd G.; Stenvinkel, Peter; Thornalley, Paul J.; Wiecek, Andrej.

In: Scientific reports, Vol. 9, No. 1, 4477, 14.03.2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients

AU - Fourdinier, Ophélie

AU - Schepers, Eva

AU - Metzinger-Le Meuth, Valérie

AU - Glorieux, Griet

AU - Liabeuf, Sophie

AU - Verbeke, Francis

AU - Vanholder, Raymond

AU - Brigant, Benjamin

AU - Pletinck, Anneleen

AU - Diouf, Momar

AU - Burtey, Stéphane

AU - Choukroun, Gabriel

AU - Massy, Ziad A.

AU - Metzinger, Laurent

AU - Argiles, Angel

AU - Beige, Joachim

AU - Brunet, Philippe

AU - Cohen, Gerald

AU - Deif, Omar Abou

AU - Evenepoel, Pieter

AU - Fliser, Danilo

AU - Fridolin, Ivo

AU - Gmerek, Andreas

AU - Jankowski, Joachim

AU - Jankowski, Vera

AU - Masereeuw, Roos

AU - Mischak, Harald

AU - Ortiz, Alberto

AU - Perna, Alessandra

AU - Rodriguez-Portillo, Juan Mariano

AU - Schanstra, Joost

AU - Spasovski, Goce

AU - Stamatialis, Dimitrios

AU - Steppan, Sonja

AU - Storr, Markus

AU - Stegmayr, Bernd G.

AU - Stenvinkel, Peter

AU - Thornalley, Paul J.

AU - Wiecek, Andrej

PY - 2019/3/14

Y1 - 2019/3/14

N2 - Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.

AB - Several microRNAs (miRNAs) have been linked to chronic kidney disease (CKD) mortality, cardiovascular (CV) complications and kidney disease progression. However, their association with clinical outcomes remains poorly evaluated. We used real-time qPCR to measure serum levels of miR-126 and miR-223 in a large cohort of 601 CKD patients (CKD stage G1 to G5 patients or on renal replacement therapy – CKD G5D) from Ghent University Hospital and 31 healthy controls. All-cause mortality and cardiovascular and renal events were registered as endpoints over a 6 year follow-up period. miR-126 levels were significantly lower from CKD stage G2 on, compared to controls. The serum levels of miR-223 were significantly lower from CKD stage G3B on. When considering overall mortality, patients with levels of either miR-126 or miR-223 below the median had a lower survival rate. Similar results were observed for CV and renal events. The observed link between the two miRNAs’ seric levels and mortality, cardiovascular events or renal events in CKD appears to depend on eGFR. However, this does not preclude their potential role in the pathophysiology of CKD. In conclusion, CKD is associated with a decrease in circulating miR-223 and miR-126 levels.

UR - http://www.scopus.com/inward/record.url?scp=85062959371&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-41101-8

DO - 10.1038/s41598-019-41101-8

M3 - Article

VL - 9

JO - Scientific reports

JF - Scientific reports

SN - 2045-2322

IS - 1

M1 - 4477

ER -

Fourdinier O, Schepers E, Metzinger-Le Meuth V, Glorieux G, Liabeuf S, Verbeke F et al. Serum levels of miR-126 and miR-223 and outcomes in chronic kidney disease patients. Scientific reports. 2019 Mar 14;9(1). 4477. https://doi.org/10.1038/s41598-019-41101-8